Q4 2025 Management View CEO Howard W. Robin described 2025 as a pivotal year, highlighting "the first positive results from the 2 Phase IIb studies of REZPEG in atopic dermatitis and alopecia areata," ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results